Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Alyssa M. Krasinskas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1801-7823; OpenAlex author ID A5051902236. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
73
Papers, trials and grants by year

2012: 3 papers · 2013: 4 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 16

  1. "Simple Mucinous Cysts" associated with pancreatic ductal adenocarcinoma: clinicopathologic and radiologic characterization of an enigmatic cyst and additional… Co-author DOI 10.1007/s00428-026-04705-w↗
  2. High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
  3. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  4. Modulation of Cancer-Associated Fibrotic Stroma by An Integrin αvβ3 Targeting Protein for Pancreatic Cancer Treatment. Co-author DOI 10.1016/j.jcmgh.2020.08.004↗
  5. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  6. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Co-author DOI 10.1172/jci.insight.130362↗
  7. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Editio… Co-author DOI 10.1245/s10434-016-5093-7↗
  8. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TN… Co-author DOI 10.1245/s10434-015-4861-0↗
  9. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreati… Last author DOI 10.1002/jso.23606↗
  10. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. Co-author DOI 10.1002/jso.23392↗
  11. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Co-author DOI 10.1038/modpathol.2013.71↗
  12. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-8-254↗
  13. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pan… Co-author DOI 10.1245/s10434-013-3161-9↗
  14. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. First author DOI 10.1007/s11605-012-1839-0↗
  15. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess "viability". Co-author DOI 10.1016/j.anndiagpath.2011.11.002↗
  16. Assessing treatment effect in pancreatic cancer. First author DOI 10.5858/arpa.2011-0144-ra↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volkan N. Adsay · 6 shared papers, 2013–2026 · strength 0.59
  2. Olca Baştürk · 5 shared papers, 2015–2026 · strength 0.54
  3. Michelle Dian Reid · 4 shared papers, 2015–2026 · strength 0.45
  4. Juan Manuel Sarmiento · 4 shared papers, 2015–2026 · strength 0.41
  5. Shishir Kumar Maithel · 4 shared papers, 2015–2026 · strength 0.41
  6. Bassel F. El‐Rayes · 4 shared papers, 2015–2026 · strength 0.41
  7. Burcu Saka · 4 shared papers, 2013–2026 · strength 0.38
  8. Pelin Bağcı · 3 shared papers, 2015–2026 · strength 0.33
  9. Gregory B. Lesinski · 2 shared papers, 2020–2026 · strength 0.32
  10. Cisel A. Mericoz · 1 shared paper, 2026 · strength 0.24
  11. Nuray Tezcan · 1 shared paper, 2026 · strength 0.24
  12. Chrystal M Paulos · 1 shared paper, 2026 · strength 0.23
  13. Emily R. Greene · 1 shared paper, 2026 · strength 0.23
  14. Cameron J. Herting · 1 shared paper, 2026 · strength 0.23
  15. Natalie K. Horvat · 1 shared paper, 2026 · strength 0.23
  16. Olatunji Boladale Alese · 1 shared paper, 2026 · strength 0.23
  17. Maria Diab · 1 shared paper, 2026 · strength 0.23
  18. Mihir Maheshkumar Shah · 1 shared paper, 2026 · strength 0.23
  19. Huamin Wang · 2 shared papers, 2021–2022 · strength 0.21
  20. Claudio Luchini · 2 shared papers, 2021–2022 · strength 0.21
  21. Iréne Esposito · 2 shared papers, 2021–2022 · strength 0.21
  22. Ralph H. Hruban MD · 2 shared papers, 2021–2022 · strength 0.21
  23. David A. Kooby · 3 shared papers, 2015–2020 · strength 0.18
  24. Herbert J. Zeh · 5 shared papers, 2012–2014 · strength 0.18
  25. Amer H. Zureikat · 4 shared papers, 2012–2014 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.